Display options
Share it on

Cancer Chemother Pharmacol. 2018 Feb;81(2):419. doi: 10.1007/s00280-017-3457-8.

Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.

Cancer chemotherapy and pharmacology

Richard Markus, Vincent Chow, Zhiying Pan, Vladimir Hanes

Affiliations

  1. Biosimilars Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA.
  2. Biosimilars Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA. [email protected].

PMID: 29159475 PMCID: PMC5778164 DOI: 10.1007/s00280-017-3457-8

Abstract

The article [A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men].

Publication Types